Conference Coverage
Conference Coverage
Imatinib rechallenge improves PFS in GIST, but not for long
Major finding: Progression-free survival of patients with advanced GIST was 1.8 months following imatinib rechallenge, compared with 0.9 months...
Conference Coverage
Chemoimmunotherapy, chemoradiotherapy add no survival in pancreatic cancer
Major finding: Median overall survival was 7.9 months for gemcitabine and capecitabine alone, 6.9 months for gemcitabine and capecitabine followed...
Conference Coverage
Bariatric surgery less efficacious in blacks
Major finding: Black patients had a smaller decline in the mean body mass index (–30%), compared with whites (–34%), and Hispanics (–32%).
Conference Coverage
Guidelines accurately predict risk of common bile duct stones
Major finding: ASGE criteria for suspected choledocholithiasis had a 75% positive predictive value for high-risk patients, and a 55% PPV for...
Conference Coverage
Risk-based strategy bests drug therapy after Crohn's surgery
Major finding: 49% vs. 67% 18-month recurrence rates for risk-based vs. standard drug therapy.Data source: Data from 174 adults in the randomized...
Conference Coverage
Home monitoring of mild acute pancreatitis safely yields savings
Major finding: Among patients with mild acute pancreatitis, there were no cases of organ failure or pancreatic necrosis and no deaths within 30...
Conference Coverage
Cold snare bests cold forceps technique for polypectomy
Major finding: Histologic eradication was 93.2% with cold snare polypectomy, compared with 75.9% for cold forceps polypectomy.Data source: A...
Conference Coverage
Error disclosure program reduced gastroenterology claims, payments
Major finding: A medical error disclosure program significantly reduced the rate of gastroenterology-related claims from 0.16% to 0.068% per 1,000...
Conference Coverage
Stem cell transplantation offers hope for resistant Crohn's
Major finding: Hematopoietic stem cell transplantation was associated with significant reductions in CDAI and SES-CD scores.Data source: A...
Conference Coverage
After HCV treatment failure, some success with boceprevir-IFN-ribavirin
Major finding: Among patients with hepatitis C infections who did not have a sustained virologic response after prior therapy, 63% had an SVR for...